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Generation of H-Ras mutant mice. To generate a mouse model for 
CS, we  targeted ES  cells by knocking  in  an oncogenic G→T 
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of  the  H-Ras  locus  (Supplemental  Figure  1;  supplemen-
tal material  available  online  with  this  article;  doi:10.1172/
JCI34385DS1).  This  strategy  allowed  the  replacement  of 
the normal GGA sequence  (Gly) with GTA (Val), a mutation 
detected in a number of CS patients that  leads to expression 


































Functional characterization of the H-Ras signaling pathway in 
H-RasG12V adult brain and E14.5 embryos. (A) Western blot 
analysis of the expression levels of wild-type H-Ras+/+ and 
mutant H-RasG12V proteins. Protein extracts (200 μg) derived 
from colons of H-Ras+/+, H-Ras+/G12V, H-RasG12V/G12V, and 
H-Ras–/– mice as well as from brain (Br), heart (He), lung (Lu), 
kidney (Ki), and liver (Li) of H-Ras+/G12V animals were subjected 
to Western blot analysis. In the case of brain, only one-fourth 
of the sample was loaded. Migration of the wild-type H-Ras 
and mutant H-RasG12V proteins is indicated by arrowheads. (B) 
Protein extracts (40 μg) from the indicated genotypes obtained 
from 2-month-old adult brains and E14.5 whole embryos were 
resolved by SDS-PAGE, transferred to a nitrocellulose mem-
brane, and blotted with antibodies against H-Ras and the non-
phosphorylated and phosphorylated forms of Erk1/2, Mek1, and 
Akt. Levels of active H-Ras protein bound to GTP (H-Ras–GTP) 
were determined by its ability to interact with the Ras binding 
domain of c-Raf. GAPDH was used as loading control.
Figure 2
H-Ras signaling in heart and kidneys of H-RasG12V mutant mice. Protein extracts (40 μg) obtained from (A) heart and kidneys of 2-month-old 
H-Ras–/–, H-Ras+/+, H-Ras+/G12V, and H-RasG12V/G12V mice and from (B) cardiomyocytes and fibroblasts isolated form neonatal hearts of H-Ras+/+ 
and H-RasG12V/G12V animals were resolved by SDS-PAGE, transferred to nitrocellulose membranes, and blotted with antibodies against H-Ras 
and the nonphosphorylated and phosphorylated forms of Erk1/2, Mek1, and Akt. GAPDH was used as loading control.
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to  be  determined.  Finally,  hemato-












Molecular analysis of H-Ras signaling 















The  activation  levels  of  these  downstream  elements  were 












Mammary gland hyperplasia in H-RasG12V virgin female mice. Red 
carmine whole-mount staining (A–C) and H&E staining of paraf-
fin sections (D–F) of mammary glands of H-Ras+/+ (A and D), 
H-Ras+/G12V (B and E), and H-RasG12V/G12V (C and F) mice. Insets 
show representative detail. Mammary glands of H-RasG12V/G12V 
mice displayed substantial white fat atrophy, greater ductal-lobu-
lillar development (arrowheads), and ductal ectasia (asterisk). 
Scale bars: 1 mm (A–C); 10 μm (D–F).
Figure 4
Facial dysmorphia. (A) Top and side views of heads of H-Ras+/+ and H-RasG12V/G12V mice illustrat-
ing the prominent forehead and blunt nose of mutant animals (arrowheads). (B) CT sections of 
H-Ras+/+ and H-RasG12V/G12V littermates. Top: Coronal projection. Arrowhead indicates choanal 
atresia. Bottom: Sagittal projection. Arrowhead indicates the shortened and depressed nasal 
bridge and premaxillar bone.
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reasoned  that  treatment with  the  TPA  tumor 


















H-RasG12V mutant mice display facial dysmorphia. 
Both H-Ras+/G12V  and H-RasG12V/G12V mice had 
























Heart and kidney defects in H-RasG12V mice. (A) Formalin-fixed hearts. (B) H&E-stained 
heart ventricular sections. Interventricular wall (IV), LV, and RV are indicated. (C) Fibro-
sis in the LV, as shown by Sirius red–stained preparations. (D) H&E-stained aortic 
valves (arrowheads). (E) H&E-stained aorta media wall (asterisks). (F) Kidney fibrosis, 
as shown by Sirius red–stained preparations. Scale bars: 1 mm (A and B); 50 μm (D); 
100 μm (C, E, and F).
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mutant lips had shorter elastic fibers that were also reduced in 
number (Supplemental Figure 9C).

























































































Cardiovascular parameters of 4-month-old wild-type and H-RasG12V mutant mice
Parameter	 H-Ras+/+	 H-Ras+/G12V	 H-RasG12V/G12V	
	 	 	 (%	change)	 (%	change)
Body weight	(g) 28.4 ± 3.1 27.6 ± 2.9 (NS) 30.4 ± 2.4 (NS)
Heart weight (mg) 174.6 ± 10.9 212.8 ± 16.6 (21.9%) 291.3 ± 7.3 (66.8%)
Cardiomyocyte area, LV (μm2)A 213.3 ± 7.7 365.4 ± 8.2 (71.3%) 492.2 ± 12.5 (130.8%)
Cardiomyocyte area, RV (μm2)A 378.0 ± 28.5 394.9 ± 27.8 (NS) 395.5 ± 26.4 (NS)
LV collagen content (μg/mg protein) 11.4 ± 0.8 15.1 ± 0.7 (32.4%) 18.1 ± 1.6 (58.8%)
Aorta media wall thickness (μm) 42.1 ± 6.1 71.7 ± 6.8 (70.3%) 69.1 ± 5.2 (64.1%)
Systolic AP, conscious (mmHg) 118.4 ± 2.7 144.8 ± 5.9 (22.3%) 170.0 ± 3.6 (43.6%)
Systolic AP, unconscious (mmHg) 69.5 ± 7.0 87.3 ± 5.5 (25.6%) 107.8 ± 9.8 (55.1%)
Diastolic AP, unconscious (mmHg) 43.6 ± 2.6 61.7 ± 5.8 (41.5%) 82.4 ± 4.0 (88.9%)
Mean AP, unconscious (mmHg 53.5 ± 0.5 75.5 ± 3.5 (41.1%) 95.0 ± 6.3 (77.6%)
Heart rate, unconscious (bpm) 553 ± 28 551 ± 14 (NS) 569 ± 16 (NS)
Heart rate, conscious (bpm) 509 ± 33 524 ± 14 (NS) 587 ± 24 (NS)
Respiratory frequency (breaths/min) 192 ± 21 205 ± 20 (NS) 209 ± 18 (NS)
Kidney collagen (μg/mg protein) 18.3 ± 2.6 27.8 ± 2.2 (52.4%) 35.7 ± 3.0 (95.1%)
Creatinine clearance (ml/min) 0.43 ± 0.03 0.19 ± 0.01 (–55.8%) 0.21 ± 0.02 (–51.2%)
Urine production (μl/d) 1,262 ± 94 1,475 ± 186 (NS) 1,310 ± 83 (NS)
Na+ excretion (mEq/d) 0.16 ± 0.03 0.15 ± 0.01 (NS) 0.14 ± 0.01 (NS)
K+ excretion (mEq/d) 0.32 ± 0.04 0.34 ± 0.02 (NS) 0.32 ± 0.03 (NS)
Cl– excretion (mEq/d) 0.47 ± 0.03 0.48 ± 0.04 (NS) 0.51 ± 0.05 (NS)
Norepinephrine (nmol/ml plasma) 1.13 ± 0.12 1.60 ± 0.21 (41.6%) 1.53 ± 0.12 (35.5%)
Epinephrine (nmol/ml plasma) 0.49 ± 0.04 0.63 ± 0.06 (NS) 0.59 ± 0.04 (NS)
Values in parentheses denote percent change compared with wild-type. AP, arterial pressure. ACross-sectional area of 
cardiomyocytes in the indicated heart section; due to the internal architecture of LV and RV, values can be only com-
pared among cardiomyocytes of the same ventricle.
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Analysis of the renin–Ang II and ET systems in H-Ras mutant mice. (A) Concentration of Ang II and ET in the plasma of mice of the indicated 
genotypes. *P < 0.01, #P < 0.05 versus wild-type. (B) Representative real-time recordings of arterial blood pressure variations upon administra-
tion of bosentan (B) and/or losartan (L). Scale bar: 1 min. (C) Quantification of mean arterial pressure upon administration of either bosentan or 
losartan. Values were taken when the arterial pressure became stabilized after the indicated treatment.
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Effect of captopril treatment on heart, aorta, and kidneys 
of H-RasG12V mutant mice. H-Ras+/+ and H-RasG12V/G12V 
mice were left untreated, or treated with captopril, for 
12 (A–F) or 24 weeks (G–L). (A and G) Formalin-fixed 
hearts. (B and H) H&E-stained heart ventricular sec-
tions. Interventricular wall, LV, and RV are indicated. (C 
and I) Fibrosis in the LV, as shown by Sirius red stain-
ing. (D and J) H&E-stained aortic valves (arrowheads). 
(E and K) H&E-stained aorta media wall (asterisks). (F 
and L) Kidney fibrosis, as shown by Sirius red staining. 
Scale bars: 1 mm (A, B, G, and H); 50 μm (D and J); 
100 μm (C, E, F, I, K, and L).
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Captopril treatment prevents the hypertensive state of H-RasG12V mutant mice
	 H-Ras+/+	 H-RasG12V/G12V
Parameter	 Untreated	 Captopril	 Untreated	 Captopril	
	 	 (%	change)A	 	 (%	change)
Systolic AP, conscious (mmHg) 111.6 ± 3.5 104.6 ± 2.4 (NS) 167.3 ± 4.2 107.8 ± 1.1 (–35.6%)
Mean AP, unconscious (mmHg) 53.5 ± 0.5 49.5 ± 5.7 (NS) 95.0 ± 6.3 53.2 ± 5.1 (–44.0%)
Aorta media wall thickness (μm) 42.1 ± 6.1 38.2 ± 4.1 (NS) 69.1 ± 5.2 42.9 ± 4.8 (–37.9%)
Ang II (pg/ml plasma) 21.9 ± 1.9 12.6 ± 2.1 (–42%) 52.5 ± 4.4 16.3 ± 2.2 (–68.9%)
Norepinephrine (nmol/ml plasma) 1.1 ± 0.1 1.2 ± 0.1 (NS) 1.5 ± 0.1 1.4 ± 0.1 (–9.8%)
Values in parentheses denote percent change compared with the untreated group. Differences between captopril-treated H-Ras+/+ and H-RasG12V/G12V mice 
were not significant. AP, arterial pressure. ACaptopril treatment in H-Ras+/+ mice induced a significant decrease in Ang II as well as in RV cardiomyocyte 
size (–18%; not shown); all other parameters measured remained constant.
Figure 8
Effect of captopril treatment on cardiovascular parameters of H-RasG12V mutant mice. Systolic arterial pressure (A), LV and RV cardiomyocyte 
area (B), and total heart weight (C) in H-Ras+/+ (white bars) and H-RasG12V (black bars) mice that were left untreated or treated with captopril for 
12 or 24 weeks. Untreated mice were controls for the 24-week treatment protocol. *P < 0.01 versus H-Ras+/+.
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Carcinogen-induced  mutations  in  the  mouse 
c-Ha-ras gene provide evidence of multiple pathways 
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